Patient preferences for treatment of castration-resistant prostate cancer in Japan: a discrete-choice experiment

BMC Urology

Table 4 Regression model results predicting medication choice (N = 133)

Attribute	Levels	b	SE	Z	p-value	OR
Administration	1-min IV injection every 4 weeks (no radiation)	1.24	0.13	9.43	0.000	3.46
	1-min IV injection every 4 weeks (some radiation)	0.39	0.12	3.27	0.001	1.48
	1-min IV injection every 4 weeks (minor radiation)	−0.25	0.09	−2.82	0.005	0.78
	Four pills taking orally once a day	2.36	0.09	25.41	0.000	10.64
	1-h IV infusion every 3 weeks	−3.75	0.10	−38.27	0.000	0.02
Overall survival	14 months	−1.53	0.04	−36.80	0.000	0.22
	16 months	−0.86	0.03	−26.46	0.000	0.42
	20 months	2.40	0.07	33.87	0.000	11.00
Time to SSE	10 months until an SSE	−1.79	0.07	−26.14	0.000	0.17
	14 months until an SSE	0.81	0.03	24.56	0.000	2.25
	16 months until an SSE	0.98	0.04	27.38	0.000	2.67
Reduction in risk of bone pain	75 % chance of suppressing bone pain	2.89	0.06	50.66	0.000	17.93
	50 % chance of suppressing bone pain	−1.42	0.03	−49.53	0.000	0.24
	25 % chance of suppressing bone pain	−1.47	0.03	−51.73	0.000	0.23
Fatigue	0 % chance of fatigue	3.06	0.07	43.25	0.000	21.25
	30 % chance of fatigue	−0.18	0.04	−4.22	0.000	0.83
	60 % chance of fatigue	−2.87	0.08	−38.02	0.000	0.06
Lost work days following treatment	0 days	1.00	0.05	21.92	0.000	2.71
	3 days	−0.43	0.02	−20.63	0.000	0.65
	5 days	−0.57	0.03	−22.54	0.000	0.57

Odds ratios (ORs) represent the adjusted relative odds of selecting a specific level vs. the mean level within any given attribute

ISSN: 1471-2490